Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Research & Development (2016 - 2026)

Cumberland Pharmaceuticals' Research & Development history spans 16 years, with the latest figure at $1.5 million for Q4 2025.

  • On a quarterly basis, Research & Development rose 19.88% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.6 million, a 15.58% increase, with the full-year FY2025 number at $5.6 million, up 15.58% from a year prior.
  • Research & Development hit $1.5 million in Q4 2025 for Cumberland Pharmaceuticals, up from $1.3 million in the prior quarter.
  • Over the last five years, Research & Development for CPIX hit a ceiling of $1.9 million in Q3 2023 and a floor of $1.1 million in Q2 2024.
  • Historically, Research & Development has averaged $1.4 million across 5 years, with a median of $1.4 million in 2021.
  • Biggest five-year swings in Research & Development: skyrocketed 38.79% in 2022 and later crashed 37.21% in 2023.
  • Tracing CPIX's Research & Development over 5 years: stood at $1.6 million in 2021, then dropped by 12.83% to $1.4 million in 2022, then fell by 10.04% to $1.3 million in 2023, then rose by 2.21% to $1.3 million in 2024, then increased by 19.88% to $1.5 million in 2025.
  • Business Quant data shows Research & Development for CPIX at $1.5 million in Q4 2025, $1.3 million in Q3 2025, and $1.5 million in Q2 2025.